TP508 (TFA)
CAT:
804-HY-P0316A-02
Size:
10 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No

TP508 (TFA)
- UNSPSC Description: TP508 TFA is a 23-amino acid nonproteolytic thrombin peptide that represents a portion of the receptor-binding domain of thrombin molecule. TP508 TFA activates endothelial NO synthase (eNOS) and stimulates production of NO in human endothelial cells. TP508 TFA activates endothelial cells and stem cells to revascularize and regenerate tissues[1][2].
- Target Antigen: NO Synthase; Thrombin
- Type: Peptides
- Related Pathways: Immunology/Inflammation;Metabolic Enzyme/Protease
- Applications: COVID-19-immunoregulation
- Field of Research: Cardiovascular Disease
- Assay Protocol: https://www.medchemexpress.com/tp508-tfa.html
- Purity: 99.44
- Solubility: H2O : 50 mg/mL (ultrasonic)
- Smiles: O=C(NCC(N[C@@H](CC1=CC=C(C=C1)O)C(N[C@@H](CCCCN)C(N2[C@@H](CCC2)C(N[C@@H](CC(O)=O)C(N[C@@H](CCC(O)=O)C(NCC(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CC(O)=O)C(N[C@@H](C)C(N[C@@H](CS)C(N[C@@H](CCC(O)=O)C(NCC(N[C@@H](CC(O)=O)C(N[C@@H](CO)C(NCC(NCC(N3[C@@H](CCC3)C(N[C@@H](CC4=CC=CC=C4)C(N[C@@H](C(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](C)N.FC(C(O)=O)(F)F
- Molecular Weight: 2426.46
- References & Citations: [1]Olszewska-Pazdrak B, et al. Nuclear Countermeasure Activity of TP508 Linked to Restoration of Endothelial Function and Acceleration of DNA Repair. Radiat Res. 2016 Aug;186(2):162-74.|[2]Olszewska-Pazdrak B, et al. Systemic administration of thrombin peptide TP508 enhances VEGF-stimulated angiogenesis and attenuates effects of chronic hypoxia. J Vasc Res. 2013;50(3):186-9|[3]Tsopanoglou NE, et al. On the mode of action of thrombin-induced angiogenesis: thrombin peptide, TP508, mediates effects in endothelial cells via alphavbeta3 integrin. Thromb Haemost. 2004 Oct;92(4):846-57.
- Shipping Conditions: Blue Ice
- Storage Conditions: -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
- Clinical Information: Phase 2